Comparable stake leader
CVI Investments, Inc.
SEC ownership of Galmed Pharmaceuticals Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001595353.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
16/22
Latest evidence
31 Mar 2026
- Public ticker
- GLMD on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
CVI Investments, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
16 of 22
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
CVI Investments, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001595353
- Issuer location
- Ramat Gan, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Galmed Pharmaceuticals Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CVI Investments, Inc.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
16/22
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 3.1%
6 rows are not safely comparable across share classes.
13D/G row: CVI Investments, Inc.
Showing 1-8 of 22 holder rows.
Quick read
CVI Investments, Inc. leads the comparable SEC ownership view at 3.1%.
16 of 22 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CVI Investments, Inc.'s linked filing trail.
Comparable ownership
Top 5
CVI Investments, Inc.
3.1%
Allen Baharaff
2.6%
TWO SIGMA INVESTMENTS, LP
1.4%
XTX Topco Ltd
0.4%
JANE STREET GROUP, LLC
0.29%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 22 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
3.1%
|
$346,666
173,333 shares
|
$0 | 30 Sep 2025 |
| Allen Baharaff |
3/4/5
13D/G
Chief Executive Officer, Director
|
2.6%
from 13D/G
|
$86,574
203,065 shares
mixed-class rows
|
— | 18 Mar 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
1.4%
|
$39,287
80,177 shares
|
— | 31 Mar 2026 |
| XTX Topco Ltd |
13F
Company
|
0.4%
|
$10,822
22,396 shares
|
— | 31 Mar 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.29%
|
$8,058
16,445 shares
|
— | 31 Mar 2026 |
| TWO SIGMA SECURITIES, LLC |
13F
Company
|
0.21%
|
$5,866
11,971 shares
|
— | 31 Mar 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.2%
|
$5,500
11,382 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.05%
|
$1,248
2,546 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Galmed Pharmaceuticals Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Allen Baharaff
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Allen Baharaff | Chief Executive Officer, Director | $86,574 | Mixed | 18 Mar 2026 | ||
| Guy Nehemya | Chief Operating Officer | $18,577 | Mixed | 18 Mar 2026 | ||
| Yohai Stenzler | Chief Accounting Officer | $18,577 | Mixed | 18 Mar 2026 | ||
| Doron Leib Cohen | Chief Financial Officer | $18,549 | Mixed | 18 Mar 2026 | ||
| Shmuel Nir | Director | $9,480 | Mixed | 18 Mar 2026 | ||
| David Sidransky | Director | $9,309 | Mixed | 18 Mar 2026 | ||
| Amir Poshinski | Director | $9,275 | Mixed | 18 Mar 2026 | ||
| Liat Hayardeny Nissimov | Chief Scientific Officer | Mixed | 18 Mar 2026 | |||
| Carol L. Brosgart | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Galmed Pharmaceuticals Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Sidransky | GLMD | Restricted Share Units | 0 | 12,500 | 18 Mar 2026 | Direct | ||||
| David Sidransky | GLMD | Restricted Share Units | 0 | 11,666 | 18 Mar 2026 | Direct | ||||
| David Sidransky | GLMD | Restricted Share Units | 0 | 1,042 | 18 Mar 2026 | Direct | ||||
| David Sidransky | GLMD | Ordinary Shares | 0 | 11,083 | 18 Mar 2026 | Direct | ||||
| Doron Leib Cohen | GLMD | Restricted Share Units | 0 | 25,000 | 18 Mar 2026 | Direct | ||||
| Doron Leib Cohen | GLMD | Restricted Share Units | 0 | 23,333 | 18 Mar 2026 | Direct | ||||
| Doron Leib Cohen | GLMD | Restricted Share Units | 0 | 2,083 | 18 Mar 2026 | Direct | ||||
| Doron Leib Cohen | GLMD | Ordinary Shares | 0 | 22,083 | 18 Mar 2026 | Direct | ||||
| Allen Baharaff | GLMD | Restricted Share Units | 0 | 100,000 | 18 Mar 2026 | Direct | ||||
| Allen Baharaff | GLMD | Restricted Share Units | 0 | 96,666 | 18 Mar 2026 | Direct | ||||
| Allen Baharaff | GLMD | Restricted Share Units | 0 | 8,889 | 18 Mar 2026 | Direct | ||||
| Allen Baharaff | GLMD | Ordinary Shares | 0 | 18 | 18 Mar 2026 | See Footnote | ||||
| Allen Baharaff | GLMD | Ordinary Shares | 0 | 103,047 | 18 Mar 2026 | Direct | ||||
| Yohai Stenzler | GLMD | Restricted Share Units | 0 | 25,000 | 18 Mar 2026 | Direct | ||||
| Yohai Stenzler | GLMD | Restricted Share Units | 0 | 23,333 | 18 Mar 2026 | Direct | ||||
| Yohai Stenzler | GLMD | Restricted Share Units | 0 | 2,083 | 18 Mar 2026 | Direct | ||||
| Yohai Stenzler | GLMD | Ordinary Shares | 0 | 22,116 | 18 Mar 2026 | Direct | ||||
| Guy Nehemya | GLMD | Restricted Share Units | 0 | 25,000 | 18 Mar 2026 | Direct | ||||
| Guy Nehemya | GLMD | Restricted Share Units | 0 | 23,333 | 18 Mar 2026 | Direct | ||||
| Guy Nehemya | GLMD | Restricted Share Units | 0 | 2,083 | 18 Mar 2026 | Direct | ||||
| Guy Nehemya | GLMD | Ordinary Shares | 0 | 22,116 | 18 Mar 2026 | Direct | ||||
| Amir Poshinski | GLMD | Restricted Share Units | 0 | 12,500 | 18 Mar 2026 | Direct | ||||
| Amir Poshinski | GLMD | Restricted Share Units | 0 | 11,666 | 18 Mar 2026 | Direct | ||||
| Amir Poshinski | GLMD | Restricted Share Units | 0 | 1,042 | 18 Mar 2026 | Direct | ||||
| Amir Poshinski | GLMD | Ordinary Shares | 0 | 11,042 | 18 Mar 2026 | Direct | ||||
| Shmuel Nir | GLMD | Restricted Share Units | 0 | 12,500 | 18 Mar 2026 | Direct | ||||
| Shmuel Nir | GLMD | Restricted Share Units | 0 | 11,666 | 18 Mar 2026 | Direct | ||||
| Shmuel Nir | GLMD | Restricted Share Units | 0 | 1,042 | 18 Mar 2026 | Direct | ||||
| Shmuel Nir | GLMD | Ordinary Shares | 0 | 11,286 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.